Comparative Pharmacology
Head-to-head clinical analysis: ISOPTO CETAPRED versus VASOCIDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOPTO CETAPRED versus VASOCIDIN.
ISOPTO CETAPRED vs VASOCIDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of sulfonamide antibiotic (sulfacetamide) and corticosteroid (prednisolone). Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Prednisolone suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene production.
Vasocidin is a combination of sulfacetamide sodium, a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking folate synthesis and bacterial growth, and prednisolone sodium phosphate, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and subsequent prostaglandin and leukotriene synthesis.
1-2 drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours; in severe cases, may be administered every 1-2 hours until response then gradually taper.
One drop of the ophthalmic suspension into the conjunctival sac of the affected eye(s) every 4 hours while awake and at bedtime for 7 days; duration may be extended based on clinical response.
None Documented
None Documented
Sulfacetamide: 7-13 hours (prolonged in renal impairment); Prednisolone: 2.5-3.5 hours (independent of dose). Total duration of anti-inflammatory effect exceeds half-life due to genomic effects.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment.
Renal: sulfacetamide is excreted unchanged in urine (30-40%); prednisolone is metabolized and excreted renally (10-20%) and fecally (30-40%) as conjugates.
Renal: 70-80% as unchanged drug; biliary/fecal: 20-30% as metabolites and unchanged drug.
Category C
Category C
Ophthalmic Antibiotic/Corticosteroid Combination
Ophthalmic Antibiotic/Corticosteroid Combination